Carmat: sales forecasts revised downwards

(CercleFinance.com) - Sales amounted to 3.
3 ME in the first half of 2024, corresponding to the sale of 7 prostheses in the commercial framework (in Germany, Italy and Poland) and 13 prostheses in the EFICAS study in France.

The operating loss for the first half of 2024 was ME25.4, a slight improvement on the first half of 2023. The net loss amounted to 26.2 ME (compared with a loss of 26.7 ME for the first half of 2023).

At June 30, 2024, the Company's cash position stood at 11.4 ME, compared with 8.0 ME at December 31, 2023.

For the second half of 2024, management anticipates annual sales of between 8 and 12 ME, compared with sales of around 14 ME as previously communicated.

The Company confirms that it is on track to achieve, by the end of the year, a recruitment rate of around 75% in the EFICAS study, around 50 centers trained for commercial implementations, a reduction of around 20% in cash consumption (operations and investments) compared with 2023, and the submission of the file for the resumption of the EFS study (United States)", says management.

Copyright (c) 2024 CercleFinance.com. All rights reserved.